Author + information
- Received December 4, 2015
- Revision received February 16, 2016
- Accepted March 12, 2016
- Published online June 27, 2016.
- Shunsuke Kubo, MD,
- Justin M. Cox, MD,
- Yukiko Mizutani, MD,
- Abhimanyu Uberoi, MD,
- Tarun Chakravarty, MD,
- Yoshifumi Nakajima, MD,
- Asma Hussaini, PA,
- Emily Tat, BA,
- Moody Makar, MD and
- Saibal Kar, MD∗ ()
- ↵∗Reprint requests and correspondence:
Dr. Saibal Kar, Heart Institute, Cedars-Sinai Medical Center, 8631 West 3rd Street, #415E, Los Angeles, California 90048.
Objectives This study reports a novel transcatheter procedure for residual mitral regurgitation (MR) after MitraClip implantation using the Amplatzer Duct Occluder II (ADO II).
Background Although the MitraClip procedure is a transcatheter treatment option for patients at high surgical risk with severe MR, management of significant residual MR after MitraClip implantation is still challenging.
Methods We describe a case series of 9 consecutive patients who underwent transcatheter deployment of the ADO II plug for significant residual MR after MitraClip implantation from April to October 2015.
Results The mean age was 79.3 ± 11.4 years. The deployment of the ADO II plug was performed at the initial MitraClip procedure in 7 patients and at the second procedure for recurrent symptoms in 2 patients. There were 2 types of residual MR seen after MitraClip implantation: residual commissural MR (n = 3) and residual intraclip MR (n = 6). The ADO II was successfully deployed with significant reduction of MR flow and left atrial pressure in all patients. The ADO II plug was retrieved in 1 patient because of device embolization to the ostial right coronary artery. However, all patients were discharged 1.8 ± 1.2 days after the procedure, with no significant MR on pre-discharge transthoracic echocardiography. In 8 patients who underwent 1-month symptomatic assessment, clinical symptoms were diminished to New York Heart Association functional class I or II.
Conclusions Transcatheter deployment of the ADO II plug was effective for the reduction of residual commissural MR and intraclip MR after MitraClip implantation. The potential role of this technique should be established for challenging cases.
Dr. Kar has received research grants and consulting fees from Abbott Vascular and St. Jude Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received December 4, 2015.
- Revision received February 16, 2016.
- Accepted March 12, 2016.
- American College of Cardiology Foundation